Exceptional response to immunotherapy in association with radiotherapy in patient with breast metastasis from urothelial carcinoma: A case report

Giulia Bonfante, Emanuela Fantinel, Cristina Masini, Franco Bergamaschi, Salvatore Micali, Bernardo Rocco

Research output: Contribution to journalArticlepeer-review

Abstract

Most common sites of metastasis of urothelial carcinoma (UC) are lungs, liver, lymph nodes and bone. Pembrolizumab, a humanized monoclonal antibody directed against programmed cell death protein-1 (PD-1), represents an effective second-line therapy for advanced UC. Radiotherapy has been shown to induce a mechanism of immunogenic cell death (ICD) resulting in immune memory and advantageous systemic effects. We present the first case of breast metastasis (BM) from a UC described in literature who had an exceptional response to second-line therapy with pembrolizumab in association with radiotherapy, showing the efficacy of combining immunotherapy and radiotherapy even in patients with atypical metastatic sites.

Original languageEnglish
Article number101444
JournalUrology Case Reports
Volume34
DOIs
Publication statusPublished - Jan 2021

Keywords

  • Breast metastasis
  • Immune checkpoint inhibitor
  • Metastatic urothelial carcinoma
  • PD-1
  • Radiotherapy

ASJC Scopus subject areas

  • Urology

Fingerprint

Dive into the research topics of 'Exceptional response to immunotherapy in association with radiotherapy in patient with breast metastasis from urothelial carcinoma: A case report'. Together they form a unique fingerprint.

Cite this